The potential of using this information to target LAM is further supported by the observation that cyclooxygenase-2, encoded by PTGS2, is over-expressed in TSC2/Tsc2-deficient cells and constitutes a therapeutic target for LAM [66]; importantly, PTGS2 is also included in the seminal breast cancer lung metastasis signature [27], being anti-correlated with TSC1/2 (this study). This evidence concerns the gene TSC2 and breast carcinoma.